Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lentigen receives NIH grant for gene therapy research in Hunter's syndrome

May 20, 2010

Odanacatib promising in phase II trial in postmenopausal women with low BMD

May 20, 2010

New compounds potentiating the activity of mutant glucosidades

May 20, 2010

Snapshots: Recent data on denosumab for postmenopausal osteoporosis

May 19, 2010

PEARL II study of Esmya meets primary efficacy and safety endpoints

May 18, 2010

Novel AMPK activators disclosed by Merck & Co. and Metabasis

May 18, 2010

Kalypsys claims novel glucose-dependent insulinotropic receptor (GPR119) ligands

May 18, 2010

Bristol-Myers Squibb claims novel MCH-R1 antagonists

May 17, 2010

Boehringer Ingelheim discloses novel 11beta-HSD1 inhibitors

May 14, 2010

Harbor Biosciences reports results of phase IIa Triolex trial in diabetes

May 13, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...